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Abstract
Background: Various animal models of renal failure have been produced and used to investigate
mechanisms underlying renal disease and develop therapeutic drugs. Most methods available to
produce such models appear to involve subtotal nephrectomy or intravenous administration of
antibodies raised against basement membrane of glomeruli. In this study, we developed a novel
method to produce mouse models of renal failure by intravenous injection of a plasmid carrying a
toxic gene such as diphtheria toxin A-chain (DT-A) gene. DT-A is known to kill cells by inhibiting
protein synthesis.
Methods:  An expression plasmid carrying the cytomegalovirus enhancer/chicken β-actin
promoter linked to a DT-A gene was mixed with lipid (FuGENE™6) and the resulting complexes
were intravenously injected into adult male B6C3F1 mice every day for up to 6 days. After final
injection, the kidneys of these mice were sampled on day 4 and weeks 3 and 5.
Results: H-E staining of the kidney specimens sampled on day 4 revealed remarkable alterations
in glomerular compartments, as exemplified by mesangial cell proliferation and formation of
extensive deposits in glomerular basement membrane. At weeks 3 and 5, gradual recovery of these
tissues was observed. These mice exhibited proteinuria and disease resembling sub-acute
glomerulonephritis.
Conclusions: Repeated intravenous injections of DT-A expression plasmid DNA/lipid complex
caused temporary abnormalities mainly in glomeruli of mouse kidney. The disease in these mice
resembles sub-acute glomerulonephritis. These DT-A gene-incorporated mice will be useful as
animal models in the fields of nephrology and regenerative medicine.
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Background
Glomerular injury has been thought to play an important
role in progression to renal failure. To search for therapeu-
tic drugs for renal failure, it is of importance to use renal
disease models in animals. There are several experimen-
tally-induced models in animals, including subtotal
nephrectomized animals, [1,2] snake venom-induced
glomerulonephritis models, [3] and glomerulonephritis
models produced by tail-vein injection of antiserum [4-7].
Transgenic mice overexpressing megsin, a novel protein of
Kunitz-type plasminogen activator inhibitor, under a
ubiquitous promoter system CAG [8] (composed of
cytomegalovirus enhancer and chicken β-actin promoter)
are reported to exhibit glomerular nephritis associated
with mesangial proliferation, accumulation of extracellu-
lar matrix and deposits of IgG [9]. Experimentally induced
models are always accompanied by fluctuation in degree
of manifestation of disease among individuals, and much
time (for example, probably over 8 months for subtotal
nephrectomy) is often required to produce them. It is
often difficult to obtain transgenic animals by the classical
pronuclear injection method, [10] and molecular charac-
terization of the introduced gene (genotyping) and its
expression must often be performed.
In this study, we intended to produce a new mouse model
of renal failure using a simple and convenient method
through in vivo introduction of non-viral DNA carrying a
toxic gene such a diphtheria toxin A-chain (DT-A) gene.
DT-A is known to kill cells by ribosylating the EF2 transla-
tion-initiation factor and inhibiting protein synthesis
[11]. It is estimated that a single molecule of the natural
protein is sufficient to kill a cell [12]. DT-A has been used
to selectively ablate tissues and cells in transgenic animals
[13-17]. We employed tail-vein-mediated injection of
plasmid DNA/lipid complex for kidney-targeted gene
transfer, since i) the method itself is non-invasive (it does
not require surgical treatment), simple and convenient,
and ii) successful gene delivery to the kidney has been
reported from several laboratories with this method [18-
24]. Furthermore, we employed the CAG promoter system
to drive DT-A gene expression, since it has been proven to
be functional in murine glomeruli, as noted previously
[9]. In this study, we consistently observed glomerular
dysfunction resembling sub-acute glomerulonephritis
after successive intravenous introduction of DT-A expres-
sion plasmid DNA/lipid complex. To our knowledge, no
other approach using this technique has been tried.
Methods
Mice
B6C3F1 (CLEA Japan, Inc., Tokyo, Japan; a hybrid
between C57BL/6N and C3H/HeN) male mice, aged 8 to
15 weeks, were used for intravenous injection of plasmid
DNA. Adult MNCE-36 transgenic mice (aged 8–15 weeks)
[25] were also used as a control for monitoring CAG pro-
moter specificity in renal tissue. They expressed enhanced
green fluorescent protein (EGFP) ubiquitously under con-
trol of the CAG promoter [25].
Mice were kept on a 12 h light/12 h dark schedule (lights
on from 0700 h to 1900 h) and allowed food and water
ad libitum. Experiments were carried out in accordance
with the Guide for the Care and Use of Laboratory Animals at
Tokai University. All efforts were made to minimize the
number of animals used and their suffering.
Preparation of plasmid vector and DNA/lipid complex
For expression of DT-A, pCAG/DT-A plasmid DNA (Fig-
ure 1A) was used. A 0.6-kb Hin dIII and Bam HI fragment
containing a DT-A gene was isolated from pBI106 [26].
This fragment was Klenow-filled and then inserted into
the Eco RI site (the site had been destroyed by T4 DNA
polymerase treatment) in the 3rd exon of rabbit β-globin
gene in pBsCAG-2, [27] a derivative of pCAGGS [8].
pBsCAG-2 [hereafter referred to as pCAG lacking the DT-
A gene (Figure 1A)] was used as a negative control. For
expression of EGFP, pCE-29 plasmid [28] (Figure 1A) was
used. In these three plasmids, the CAG promoter was
employed for systemic expression of a downstream cDNA
or gene.
All solutions used for intravenous DNA injection were
prepared at a volume of 200 µl/mouse. Forty µl of
FuGENE™6 (Boehringer Mannheim GmbH, Mannheim,
Germany), a transfection reagent (lipid), was diluted with
60 µl of PBS(-), and then added to 20 µg of circular plas-
mid DNA dissolved in 100 µl of PBS(-) according to the
manufacturer's protocol. For control injection (mock
injection), a solution containing 40 µl of FuGENE™6 dis-
solved in PBS(-) (without DNA) or PBS(-) only was
prepared.
Intravenous injection of plasmid DNA/FuGENE™6 
complex
Solution containing plasmid DNA/FuGENE™6 complex,
FuGENE™6 only or PBS(-) only was injected into the tail
vein of unanesthetized B6C3F1 males with a 1-ml plastic
disposable syringe (Terumo, Tokyo, Japan) fitted with a
27-gauge needle (Nipro, Osaka, Japan). Injections were
performed at a speed of 200 µl/8–10 sec. This injection
was repeated every day for up to 6 days (Figure 1B).
Isolation of tissues and preparation of genomic DNA for 
polymerase chain reaction (PCR) analysis
Genomic DNA of organs was isolated as previously
described [29] with several modifications [30]. PCR
amplification reactions were performed, as previously
described [31]. One set of primers (DTA-S and DTA-2RV)
for detection of the introduced pCAG/DT-A is listed inBMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/4
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(A) Schematic diagram of the vector constructs pCAG/DT-A, pCAG and pCE-29 Figure 1
(A) Schematic diagram of the vector constructs pCAG/DT-A, pCAG and pCE-29. Small arrows beneath the pCAG/DT-A plas-
mid indicate positions and directions of primers used for PCR and RT-PCR. The pCAG/DT-A vector could be identified by 
PCR using the primer set DTA-S/DTA-2RV. DT-A mRNA synthesized from the CAG promoter can be identified by RT-PCR 
using the primer set βA-1/DTA-RV. Arrowheads above the CAG promoter indicate the transcription initiation site. Thick line 
indicates a sequence corresponding to a portion of the 2nd intron, 3rd exon and 3'-noncoding region of rabbit β-globin gene. 
Red line indicates the sequence of pBluescript SK(-) vector. A portion of the 1st intron of the chicken β-actin gene is shown by 
a green line. ATG, translation initiation site; CAG, cytomegalovirus enhancer and chicken β-actin gene promoter; DT-A, diph-
theria toxin A-chain gene; EGFP, enhanced green fluorescent protein cDNA; pA, polyadenylation site of rabbit β-globin gene; 
SVpA, polyadenylation sites of SV40 gene. (B) Schematic diagram of the procedure of intravenous injection (IVI) of plasmid 
DNA/lipid complex and sampling schedule. IVI was performed every day for up to 6 days. Sampling was performed on 4 days 
(4-d) and 3 (3-w) and 5 weeks (5-w) after the final IVI. 1-d, 1 day. (C) (a,b) EGFP fluorescence in the kidneys from MNCE-36 
transgenic mouse (a) and its non-transgenic littermate (b). Glomeruli [indicated by arrows in (a)] and a portion of renal tubules 
[indicated by arrowheads in (a)] were positive for EGFP fluorescence in the transgenic mouse, but the non-transgenic mouse 
did not exhibit fluorescence. (c,d) Immunohistochemical staining of the glomeruli from the MNCE-36 mouse (c) and its non-
transgenic littermate (d) using anti-GFP antibodies. The surface of the transgenic glomerulus [indicated by arrows in (c)] 
appeared to have reacted intensely with the antibodies, while the non-transgenic control glomerulus did not react with the 
antibodies. (e,f) Immunoelectron microscopic analysis of the MNCE-36 kidney reacted with anti-GFP antibodies. Reactive sub-
stances (indicated by arrows) were predominantly observed in glomerular epithelium (epi) (e) and slightly in glomerular 
endothelium (end) (f). b.m., basement membrane; e.l., endothelial lumen.BMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/4
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Figure 1A. This primer set yields 267-bp fragments. DTA-
S (5'-ATG TTG TTG ATT CTT CTA AAT-3') and DTA-2RV
(5'-GCG AGA ACC TTC GTC AGT CCT-3') correspond to
nucleotides 87 to 107 and 333 to 353 in the DT-A gene
sequence, [26] respectively.
Reverse transcriptase (RT)-PCR analysis
Total RNA was isolated from organs by the method of
Chomczynski and Sacchi [32]. RT-PCR was performed
using sense primer βA-1 (Figure 1A) and reverse primer
DTA-RV (Figure 1A), as previously described [33]. βA-1
(5'-TCT GAC TGA CCG CGT TAC TCC CAC A-3') corre-
sponds to nucleotides -1,011 to -987 of the chicken β-
actin gene sequence, [34] and DTA-RV (5'-CAG AGT ATC
CCG CAG CGT CGT-3') to nucleotides 254 to 274 in the
5' region of the DT-A gene sequence [26]. The primer set
(βA-1/DTA-RV) was designed to produce PCR fragments
of 300 bp. The PCR primer set (mβA-S/mβA-RV) [33] for
detection of mouse β-actin mRNA was also used.
Renal function
Urine samples were collected by grasping mice and imme-
diately transferred to urine testing paper (#1333; Sankyo
Medicals Inc., Tokyo, Japan) to evaluate the levels of pro-
tein and occult blood semi-quantitatively. Serum was pre-
pared by separation of the coagulated whole blood by
cava puncture after urine collection under pentobarbital-
induced anesthesia. Serum concentrations of blood urea
nitrogen (BUN), creatinine (CRT), Na+, Cl-, and K+ were
measured by an automated analyzer in SRL Lab. Ltd.
(Tokyo, Japan).
Histological processing of organs and inspection of 
fluorescence
After mice introduced with plasmid DNA/FuGENE™6
complex, FuGENE™6 only or PBS(-) only were perfused
with 4% paraformaldehyde (PFA) in PBS(-), major organs
(including brain, heart, lung, pancreas, liver, kidney and
intestine) were dissected, post-fixed with 4% PFA in PBS(-
) at 4°C for over 10 days except for the kidney, and then
subjected to standard histological processing. The kidney
was cut into several slices approximately 3–5 mm thick-
ness. Some specimens were subjected to immunohisto-
chemical, immunoelectron microscopic and electron
microscopic analyses, as described below. Major organs
including the kidney were paraffin-embedded and then
stained with hematoxylin-eosin (H-E). Some of these par-
affin-embedded specimens were stained with periodic
acid-Schiff (PAS), and periodic acid-Schiff-methenamine
silver (PAM).
For inspection of EGFP fluorescence, B6C3F1 mice intra-
venously injected with pCE-29/FuGENE™6 complex,
MNCE-36 transgenic mice or their non-transgenic litter-
mates were perfused with 4% PFA in PBS(-). Organs were
dissected from these mice and cut into several pieces
approximately 3–5 mm in thickness. Some of these speci-
mens were immediately subjected to observation for
EGFP fluorescence under a fluorescence stereomicroscope
(SZX12, Olympus, Tokyo, Japan) with DM505 filters
(BP460–490 and BA515IF, Olympus). This allowed us to
examine gene expression directly in the intact organ,
thereby avoiding potential artifacts that may be intro-
duced during sample preparation for histochemical
examination. The other specimens were further fixed with
4% PFA in PBS(-) at 4°C overnight, dehydrated in a
sucrose series in PBS(-) and embedded in O.C.T. com-
pound (Tissue-Tek, No. 4583, Miles Scientific, Naperville,
IL) for cryostat sectioning. The sections were observed for
EGFP fluorescence using a Olympus BX60 microscope
under UV illumination. Microphotographs of the speci-
mens were taken using a digital camera (FUJIX HC-300/
OL; Fuji Film, Tokyo, Japan) attached to an Olympus
BX60 or SZX12 microscope and printed out using a digital
color printer (CP700DSA; Mitsubishi, Tokyo, Japan).
For immunohistochemistry and immunoelectron micro-
scopic analyses, mice were first perfused with 4% PFA in
PBS(-). The kidneys were isolated, sliced and further fixed
with 4% PFA in PBS(-) at 4°C for 3 days, treated with 10%
sucrose in PBS(-) at 4°C for 3 days, embedded in O.C.T.
compound, and frozen at -80°C. Sections (4 µm thick)
were cut with a cryostat and subjected to immunohisto-
chemistry using anti-GFP antibodies (#8367-2; Living
Colors A.v. Peptide Polyclonal Antibody, Clontech, MA)
and an avidin-biotin coupling (ABC) peroxidase tech-
nique performed with the aid of a kit (Vectstain Elite; Vec-
tor, Burlingame, CA). The sections were washed in PBS(-)
and incubated with 0.02% diaminobenzidine (DAB) in
0.05 M Tris buffer (pH7.6) containing 0.01% H2O2 for 3
min. After washing in PBS(-), the sections were fixed with
2.5% glutaraldehyde for 3 min at room temperature. The
sections were washed in PBS(-), post-fixed with 1%
osmium tetroxide in 0.1 M sodium phosphate buffer (pH
7.4) for 3 min, washed in distilled water, dehydrated in a
graded ethanol series, and flat-embedded in Epon 812
(TAAB Laboratories Equipment Ltd., Berkshire, United
Kingdom). After polymerization of the Epon 812, we
examined the sections by light microscopy, clipped
selected fields, and cut them with an ultramicrotome into
ultrathin sections, which were then examined for DAB-
stained sites with an electron microscope (JEM-1200EX;
JEOL Ltd., Tokyo, Japan).
For electron microscopic analysis, after perfusion with 4%
PFA in PBS(-), the kidneys were isolated, sliced, immersed
for 2 h in 0.1 M sodium phosphate buffer (pH 7.4) con-
taining 2% glutaraldehyde, post-fixed in 2% osmium
tetroxide in 0.1 M cacodylate buffer for 1 h, dehydrated in
acetone, and embedded in Epon 812. Semithin sectionsBMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/4
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were stained with toluidine blue and examined by light
microscopy to identify regions of the blocks containing
several glomeruli. Ultrathin sections were stained with
uranyl acetate and lead acetone and were examined with
a JEM-1200EX electron microscope.
Glomerular morphometry
To evaluate the extent of glomerular nephritic lesions, at
least 100 glomeruli in H-E-stained sections were ran-
domly chosen per kidney, and lesions were quantified
and graded from 0 to 2: score 0, normal; score 1, weak to
mild change (exhibiting mild mesangial cell proliferation
and mesangial matrix expansion); score 2, severe change
(exhibiting lobular structure of glomeruli and adhesion of
glomeruli to the inner surface of Bowman's capsule). The
extent of glomerular lesions was expressed as a score (%)
using the following formula: The number of glomeruli
exhibiting each score/total numbers of glomeruli
examined.
Statistical analysis
All data are means ± SD (n = 4 to 6 for each treatment
group). For comparison of pairs, statistical analysis the
unpaired t-test was used with the level of significance set
at P < 0.05.
Results
Role of the CAG promoter in kidney-targeted gene 
expression
In this study, we used CAG promoter for expression of DT-
A in mouse kidney, since it has been suggested to be active
in murine kidney, particularly glomeruli [9]. Cryostat sec-
tions of MNCE-36 kidney revealed bright fluorescence in
glomeruli [indicated by arrows in (a) of Figure 1C] and
relatively weak fluorescence in some portions of tubules
[indicated by arrowheads in (a) of Figure 1C]. Non-trans-
genic control kidney was completely negative for fluores-
cence [(b) of Figure 1C]. Other lines, MNCE-39 and -53,
[25] exhibited similar distributions of EGFP in kidney
(data not shown), eliminating the possibility that the
above findings were due to the transgene integration site
used. Immunohistochemical staining of cryostat sections
revealed that immunoreactive deposits were present on
the surface of glomerulus facing Bowman's space [indi-
cated by arrows in (c) of Figure 1C]. Non-transgenic kid-
ney was completely negative for immunoreaction [(d) of
Figure 1C]. Immunoelectron microscopic analysis further
revealed that immunoreactive deposits were present
mainly in glomerular epithelium [indicated by arrows in
(e) of Figure 1C] and slightly in glomerular endothelium
[indicated by arrows in (f) of Figure 1C]. A portion of
mesangial cells was also found to be slightly positive for
staining by the antibody (data not shown). Thus, the CAG
promoter was concluded to be predominantly active in
glomerular epithelial cells.
Determination of optimal transfection parameters
We used FuGENE™6 as reagent for tail-vein-mediated
gene delivery to mouse kidney, since it has been proven
useful for gene delivery to mid-gestational fetuses after
intravenous injection [35]. We performed 6 repeated
injections of pCE-29/FuGENE™6 complex for up to 6
days, and examined fluorescence on day 4. Each treatment
yielded deposition of EGFP fluorescence in some organs
including the lung, heart, kidney and pancreas. The inner
surface of heart (indicated by arrows in Figure 2a), and a
portion of inner area (indicated by arrows in Figure 2b)
and outer surface (indicated by arrows in Figure 2c), prob-
ably endothelial cells, of lung were successfully trans-
fected. This is probably because DNA/lipid complexes
have maximal accessibility to these cells upon intravenous
injection. In the kidney, EGFP expression was observed in
almost all (more than 80%) of the glomeruli (indicated
by arrows in Figure 2d), although the intensity of staining
varied among glomeruli. Expression in kidney declined
when inspected on day 7 (data not shown). Other organs
(including brain, liver, intestine and spleen) did not fluo-
resce at a detectable level. Cryostat sectioning of EGFP-
expressing kidney confirmed the previous finding that
EGFP fluorescence was localized to glomeruli (indicated
by arrows in Figures 2e,2f) and a portion of renal tubules
(indicated by arrowheads in Figure 2e), although the dis-
tribution and intensity of EGFP fluorescence were more
patchy and weaker than in the MNCE kidneys [Figures
2e,2fvs. (a) of Figure 1C]. These findings indicated that the
overall pattern of EGFP expression in kidney after tail-
vein-mediated gene transfer was almost the same as that
in MNCE transgenic kidney.
Histological examination for renal damage-study on day 4
B6C3F1 male mice were injected 6 times with pCAG/DT-
A/FuGENE™6 complex, pCAG/FuGENE™6 complex,
FuGENE™6 only (mock injection) or PBS(-) only (mock
injection). All mice in both experimental and control
mock-injected groups appeared healthy during the 6-day
gene delivery periods, with the exception that one mouse
injected with pCAG/DT-A/lipid complex died suddenly
immediately after the final injection. Major organs were
immediately dissected from the dead mouse and sub-
jected to molecular biological analysis for detection and
expression of pCAG/DT-A. The remaining mice were first
subjected to collection of serum and urine, and then per-
fused with 4% PFA in PBS(-) prior to isolation of organs
and subsequent histological analyses on day 4 and weeks
3 and 5.
H-E staining of the kidneys sampled on day 4 after injec-
tion of pCAG/DT-A/FuGENE™6 complex revealed
remarkable alterations of glomerular components. All
specimens (8 tested) exhibited similar phenotypic altera-
tions. These alterations included formation of segmentalBMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/4
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glomeruli (glomerular lobulation) (Figures 3d,3e,3f),
mesangial cell proliferation (as evaluated by the presence
of mitotic figures in the mesangial region; Figures
3a,3d,3e,3f), loss of Bowman's space probably due to
mesangial cell proliferation (indicated by arrows in Fig-
ures 3a,3b), appearance of cellular degeneration (indi-
cated by arrows in Figures 3c,3e), and attenuation of
glomerular capillaries (indicated by arrowheads in Figures
3c,3f). Notably, inflammatory response (infiltration of
mononuclear lymphocytes) in the tubulointerstitium was
also observed in some specimens (indicated by arrow-
heads in Figure 3g). However, none of the mice receiving
pCAG/FuGENE™6 complex exhibited such glomerular
abnormalities (6 kidneys examined; Figure 3j). All mice
receiving FuGENE™6 only or PBS(-) exhibited only nor-
mal glomeruli (each of 8 kidneys examined; Figure 3k).
The kidneys of intact mice were also normal (2 kidneys
examined; Figure 3l). Inspection of H-E-stained speci-
mens revealed no clear abnormality in the other major
organs (including brain, heart, lung, pancreas, liver and
intestine) tested, although heart, lung and pancreas have
previously been identified as susceptible to transfection
by exogenous DNA (see Figures 2a,2b,2c).
Electron microscopic analysis of the kidneys (2 kidneys
from different mice) treated with pCAG/DT-A/FuGENE™6
complex confirmed the above findings. Hypercellularity
in the mesangial area of the DT-A expression vector-
treated mice was due to increase in number of mesangial
cells, accompanied by expansion of matrix (Figure 4a).
The most prominent abnormalities observed were forma-
tion of focal deposits in glomerular basement membrane
(GBM) (indicated by arrows in Figures 4c,4d,4e,4f). Ini-
tially, small deposits were also noted in GBM (indicated
by arrowheads in Figures 4d,4e). However, other glomer-
ular components including endothelial and epithelial
EGFP fluorescence in 4% paraformaldehyde-fixed heart (a), lung (b,c) and kidneys (d-f) of mice injected 6 times with pCE-29/  FuGENE™6 complex Figure 2
EGFP fluorescence in 4% paraformaldehyde-fixed heart (a), lung (b,c) and kidneys (d-f) of mice injected 6 times with pCE-29/ 
FuGENE™6 complex. (a) Inner surface of the heart cut into slices. Note that the luminal surface of the heart exhibited focal 
and slight EGFP fluorescence (indicated by arrows). (b,c) Inner surface (b) of the lung cut into slices and outer (c) surface of the 
lung. Note focal or patchy expression of EGFP fluorescence in each sample (indicated by arrows). (d) Inner surface of the kid-
ney cut into slices. Note that several glomeruli expressed EGFP fluorescence (indicated by arrows). (e) A cryostat section of 
the kidney in (d). Patchy expression for EGFP fluorescence (indicated by an arrow) in glomeruli was noted. Also, some renal 
tubules exhibited faint fluorescence (indicated by arrowheads). (f) A figure magnified from the boxed region in (e). EGFP fluo-
rescence was patchy in the glomerulus (indicated by arrows).BMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/4
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H-E staining of glomeruli and renal tubules in the kidneys of mice injected 6 times with pCAG/DT-A/FuGENE™6 complex (a- i), pCAG/FuGENE™6 complex (j) or PBS(-) only (k) on day 4 (a-g) and weeks 3 (h) and 5 (i) Figure 3
H-E staining of glomeruli and renal tubules in the kidneys of mice injected 6 times with pCAG/DT-A/FuGENE™6 complex (a-
i), pCAG/FuGENE™6 complex (j) or PBS(-) only (k) on day 4 (a-g) and weeks 3 (h) and 5 (i). On day 4, proliferation of mesang-
ial cells, which causes loss of Bowman's space [indicated by arrows in (a) and (b)] and attenuation of glomerular capillaries [indi-
cated by arrowheads in (c)] were remarkable. In some cases, findings of cellular degeneration [indicated by arrows in (c) and 
(e)] and appearance of lobular segmental structure of glomerulus (d-f) were observed. Infiltration of lymphocytes into intersti-
tum and renal tubules [indicated by arrowheads in (g)] was sometimes observed. However, no gross alteration in glomeruli 
was noted in the groups with injection of pCAG/FuGENE™6 complex (j) and of mock injections with FuGENE™6 only (data 
not shown) or PBS(-) only (k). On week 3, slight recovery was observed in the mice treated with pCAG/DT-A/FuGENE™6 
complex, although debris [indicated by an arrow in (h)] existed in Bowman's space. By week 5, the morphology of glomeruli 
had almost completely recovered, although proteinaceous substances were often observed in Bowman's space (i). (l), Glomer-
ulus of intact kidney.BMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/4
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Electron microscopic analysis of affected glomeruli (a, c-f, h), and tubules (g) on day 4 (a, c-g) and week 5 (h) after injection of  pCAG/DT-A/FuGENE™6 complex Figure 4
Electron microscopic analysis of affected glomeruli (a, c-f, h), and tubules (g) on day 4 (a, c-g) and week 5 (h) after injection of 
pCAG/DT-A/FuGENE™6 complex. In the affected glomeruli (a), severe matrix expansion with numerous electron-dense 
deposits was detected in the mesangial matrix. The capillary lumen of endothelial cells was deformed, probably due to prolifer-
ation of active mesangial cells. Degeneration of mesangial cells was sometimes observed [indicated by an arrow in (a)]. In con-
trast, the control glomeruli derived from mock injection of PBS(-) on day 4 (b) exhibited normal appearance. Notably, 
formation of focal deposits in glomerular basement membrane was often remarkable [indicated by arrows in (c-f)]. The initial, 
small deposits of glomerular basement membrane are shown by arrowheads in (d) and (e). Incorporation of lipids, probably 
DNA/lipid complexes that had been re-uptaken by renal tubules, was noted in the cytoplasm of renal tubules [indicated by 
arrows in (g)]. On week 5, nearly normal glomerular structure was observed (h).BMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/4
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cells appeared almost normal. These cells thus survived
without suffering transfection by the DT-A expression
plasmid/lipid complex. Degeneration of mesangial cells
was sometimes observed (indicated by the arrow in Figure
4a). The control kidney mock-injected with PBS(-) exhib-
ited only normal glomerular structure (2 kidneys from
different mice; Figure 4b). These phenotypic alterations
were thus thought to have initiated from cellular ablation
of glomerular epithelium, glomerular endothelium and
some mesangial cells, followed by successive formation of
focal deposits in GBM and mesangial cell proliferation.
Electron microscopic analysis revealed that the tubules
sometimes had electron-dense droplets, probably due to
readsorbtion of DNA/lipid complex (indicated by arrows
in Figure 4g).
On morphometric analysis of the H-E-stained kidney
specimens derived from injection of pCAG/DT-A/
FuGENE™6 complex, the percentage of glomeruli scored 2
was approximately 80 % [(4-d) column in Figure 5]. In
the kidneys with injection of pCAG/FuGENE™6 complex
and those from mock injections, the percentages of
glomeruli scored 2 were all below 3% [(4-d) column in
Figure 5]. When the paraffin-embedded specimens
derived from the kidney treated with pCAG/DT-A/
FuGENE™6 complex were stained for PAS and PAM, there
was extensive deposition of PAM-positive materials in the
mesangial area (2 kidneys from different mice examined;
Figure 6f), indicating expansion of mesangial matrix. The
PAS-positive materials did not differ among specimens
tested (Figure 6bvs. Figure 6e).
Glomerular H-E staining scores in the kidney samples on day 4 (4-d) and weeks 3 (3-w) and 5 (5-w) after repeated injections of  pCAG/DT-A/FuGENE™6 complex, pCAG/FuGENE™6 complex or mock injections [FuGENE™6 only or PBS(-) only] Figure 5
Glomerular H-E staining scores in the kidney samples on day 4 (4-d) and weeks 3 (3-w) and 5 (5-w) after repeated injections of 
pCAG/DT-A/FuGENE™6 complex, pCAG/FuGENE™6 complex or mock injections [FuGENE™6 only or PBS(-) only]. At 
least 100 glomeruli in the H-E-stained sections were randomly chosen per kidney and the lesions were quantified. A total of 4 
kidneys for each group were inspected. The glomerular lesions were graded from 0 to 2: score 0, normal; score 1, weak to 
mild change (exhibiting mild mesangial cell proliferation and mesangial matrix expansion); score 2, severe change (exhibiting 
lobular structure of glomeruli and adhesion of glomeruli to the inner surface of Bowman's capsule).BMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/4
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Histological examination for renal damage-study at weeks 
3 and 5
The next step was to evaluate whether the above-men-
tioned renal lesions would persist over 3 weeks after final
administration of a DT-A expression vector.
At week 3, gradual recovery of injured glomeruli was
observed in all mice (8 kidneys) tested that had been
injected with pCAG/DT-A/FuGENE™6. Almost all glomer-
uli (more than 80%) at this stage were scored 1 [(3-w) col-
umn in Figure 5]. Notably, a portion of glomeruli was still
enriched with proliferated mesangial cells, and cellular
debris was often observed in the Bowman's space (indi-
cated by the arrow in Figure 3h). PAS and PAM staining
also confirmed the above finding that mesangial deposi-
tion was much reduced compared with that in the sam-
ples collected on day 4 (2 kidneys from different mice;
Figures 6e,6fvs. Figures 6h,6i, respectively).
At week 5, several abnormal findings found in glomeruli
sampled at week 3 had nearly been lost: These included
expansion of glomerular capillaries and reduction of
mesangial cell proliferation and mesangial matrix,
although proteinaceous substances were often observed
in the Bowman's space (Figure 3i). Electron microscopic
observation revealed almost complete recovery of the
glomeruli (Figure 4h). This was confirmed by morpho-
metric analysis of H-E-stained specimens: Almost all
glomeruli (more than 70%) at this stage were scored 0 [(5-
w) column in Figure 5]. Staining with PAS and PAM
revealed glomerular structures indistinguishable from
PAS and PAM staining of kidney sections sampled day 4 (d-f)  and weeks 3 (g-i) and 5 (j-l) after intravenous administration  of pCAG/DT-A/FuGENE™6 complex Figure 6
PAS and PAM staining of kidney sections sampled day 4 (d-f) 
and weeks 3 (g-i) and 5 (j-l) after intravenous administration 
of pCAG/DT-A/FuGENE™6 complex. Note that increased 
deposition of mesangial matrix, as revealed by increased 
staining by PAM, was evident in the glomerulus on day 4 (f), 
but that in later stages (weeks 3 and 5) such deposits were 
decreased (i,l). (a-c) indicate intact kidney.
(A) Detection of exogenous pCAG/DT-A by PCR analysis Figure 7
(A) Detection of exogenous pCAG/DT-A by PCR analysis. 
Genomic DNA was extracted from organs of the mice 
injected with pCAG/DT-A/FuGENE™6 complex or PBS(-) 
(mock injection). Detection of pCAG/DT-A was performed 
by PCR using DTA-S/DTA-2RV primer set (see Figure 1A). 
This PCR yielded a product of 267 bp [indicated by an arrow 
in (A)]. C indicates that tail DNA (1 µg) from a B6C3F1 
mouse was directly subjected to PCR as a negative control. 
PC indicates that pCAG/DT-A (4 ng) was subjected to PCR 
as a positive control. (B) Detection of DT-A mRNA by RT-
PCR analysis. Detection of DT-A mRNA was performed by 
RT-PCR using βA-1/DTA-RV primer set (see Figure 1A), 
which yielded an expected band of 300 bp [indicated by an 
arrow in (B)]. In the lower panel of (B), the expression pat-
tern of endogenous β-actin mRNA is indicated. Lu, lung; Br, 
brain; H, heart; K, kidney; In, intestine; L, liver. C-1 indicates 
that tail DNA (1 µg) from a B6C3F1 mouse was directly sub-
jected to PCR. C-2 indicates that tail DNA (1 µg) from a 
B6C3F1 mouse was directly subjected to reverse transcrip-
tion and the resulting solution was then PCR-amplified. PC 
indicates that pCAG/DT-A (4 ng) was subjected to RT-PCR 
as a positive control. A few non-specifically amplified bands 
above the 300-bp band were observed in lane C-2, and 
approximately 600-bp bands [indicated by an arrowhead in 
(B)], probably corresponding to the products obtained 
through amplification of pCAG/DT-A, were also seen in lane 
PC.BMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/4
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those of normal kidney specimens (Figures 6b,6cvs. Fig-
ures 6k,6l, respectively).
PCR and RT-PCR analyses for DT-A expression vector and 
mRNA in major organs
To obtain evidence that the abnormalities in kidneys
mentioned above are in fact caused by introduction and
expression of a DT-A expression vector, we performed
PCR and RT-PCR analyses. As shown in Figure 7A, the
pCAG/DT-A introduced was detected in all major organs
tested (including brain, where it is believed to be difficult
for exogenous substances in blood to be transferred due to
the blood-brain barrier). RT-PCR analysis revealed that
several organs (including lung, heart, kidney and intes-
tine) exhibited a band of the expected size (Figure 7B).
Organs derived from mock injection [PBS(-) only] were
negative for expression of DT-A mRNA (Figure 7B). These
findings suggest that the glomerular injuries reported here
were actually caused by expression of the DT-A gene.
Renal function after injection of DT-A expression vector/
lipid complex
Serum levels of CRT, an endogenous marker of renal func-
tion, were transiently elevated in the pCAG/DT-A/
FuGENE™6 complex-administered mice, with a peak at
day 4, while the other biochemical markers including
BUN, Na+, Cl-, and K+ were unaltered through day 4, and
at weeks 3 and 5 (Figure 8). Mice treated with pCAG/
FuGENE™6 complex, FuGENE™6 only or PBS(-) only
exhibited no change in serum parameters at any time-
point tested (Figure 8).
Urine levels of proteins were significantly elevated in the
mice treated with pCAG/DT-A/FuGENE™6 complex
through day 4 and at weeks 3 and 5 (Table 1). Further-
more, urine levels of occult blood were transiently ele-
vated in the pCAG/DT-A/FuGENE™6 complex-
administered mice, with a peak at day 4 (Table 1). These
findings suggest that the renal damage caused by DT-A
expression is correlated well with alterations in biochem-
ical parameters in serum and urine.
Discussion
In this study we used the CAG promoter for kidney-tar-
geted expression of the DT-A gene. It may be asked why
was used for renal cell ablation without a kidney-specific
promoter. In many applications, such tissue-specific
promoters are often weak relative to stronger but constitu-
tively expressing viral promoters [36]. In contrast, several
studies have demonstrated that the CAG promoter pro-
duces high levels of gene expression in vivo. [37,38]. How-
ever, it is quite possible that tail-vein-mediated gene
delivery of pCAG/DT-A would have deleterious effects on
a variety of organs or tissues, because of the ubiquitous
nature of CAG promoter activity itself. However, we
found here that when a CAG-directed EGFP expression
vector was introduced intravenously, gene expression was
limited to only a few organs such as kidney, heart, lung
and pancreas. In kidney, gene expression was confined to
glomeruli and a portion of renal tubules (see Figures
2d,2e,2f). Except for the kidney no histological abnormal-
ity was noted in the latter three organs even after repetitive
introduction of a DT-A expression vector. Heart, lung and
pancreas may thus be more resistant to the toxicity of DT-
A than kidney. Furthermore, all the treated mice, except
one mouse which suddenly died immediately after the
final injection, survived healthy through 5 weeks after
DNA introduction. We therefore believe that intravenous
injection of CAG promoter-directed non-viral DNA con-
fers glomerulus-targeted gene expression.
It may be asked why we employed repeated injections of
non-viral DNA for transfection of renal components. To
date, various methods to deliver gene constructs to renal
cells have been reported, including introduction of
plasmid DNA/lipid complex or viral DNA to renal artery
[39-43] or introduction of plasmid DNA to renal artery
and subsequent in vivo electroporation [44]. All these
require surgery and are therefore invasive. On the other
hand, successful gene delivery to kidney by single intrave-
nous injection of non-viral DNA/liposome complex has
also been described [18-20,23,24]. In our preliminary
test, we found that 6, but not single and 3, successive
introductions of DNA/lipid complex resulted in good in
vivo transfection efficiency for renal cells.
Notably, EGFP expression in glomeruli and renal tubules
after repeated introduction of pCE-29/lipid complex was
weaker and sometimes more patchy than in the MNCE-36
transgenic mice carrying pCE-29 element [(a) in Figure
1Cvs. Figures 2e,2f]. Furthermore, expression declined
within a week. This mode of transient gene expression
suggests that intravenous gene introduction of a DT-A
expression vector would cause mild or partial ablation of
glomerular compartments and tubules, which may in turn
allow proliferation of renal cells, particularly mesangial
cells, following cessation or decline of expression of an
exogenous gene. This situation appears to contrast to that
of snake venom-mediated acute mesangiolysis [3], which
is caused by severe injuries of glomerular compartments.
Furthermore, DT-A-mediated renal cell ablation appears
to be different from the anti-Thy 1.1 model of
experimental glomerulonephritis. In this model, acute
mesangiolysis is induced by injected anti-thymocyte anti-
body, and focal segmental mesangial proliferation com-
mences on around 6 days after antibody injection and the
altered phenotype persists for about 30 days, which
would hamper regeneration of glomeruli themselves [45].
This persistence is probably due to immune complex
formed in situ with consecutive complement activation inBMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/4
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Serum levels of BUN, CRT, Na+, K+ and Cl- in the mice repeatedly injected with pCAG/DT-A/FuGENE™6 complex, pCAG/ FuGENE™6 complex, FuGENE™6 only or PBS(-) only Figure 8
Serum levels of BUN, CRT, Na+, K+ and Cl- in the mice repeatedly injected with pCAG/DT-A/FuGENE™6 complex, pCAG/
FuGENE™6 complex, FuGENE™6 only or PBS(-) only. Serum sampling was performed on day 4(4-d) and weeks 3 (3-w) and 5 
(5-w).
Table 1: Measurement of levels of protein and occult blooda in urine of mice sampled on day 4 and weeks 3 and 5 after 6 repeated 
administrations of pCAG/DT-A/FuGENE™6, pCAG/FuGENE™6 complex, FuGENE™6 only or PBS(-) only
Treatment day 4 week 3 week 5
Protein OCCULT Protein OCCULT Protein OCCULT
pCAG/DT-A/FuGENE™6 complex + + + - +/- -
pCAG/FuGENE™6 complex - - - - - -
F u G E N E ™ 6  o n l y ------
PBS(-) only - - NDb ND ND ND
aLevels of protein and occult blood in urine were measured using a urine testing paper. bND = not determined.BMC Nephrology 2004, 5 http://www.biomedcentral.com/1471-2369/5/4
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the mesangium and an overproduction of extracellular
matrix components that may contribute to subsequent
development of glumerulosclerosis [46].
As observed on electron microscopic analysis, the major
defects in glomeruli of the mice treated with DT-A expres-
sion vector/lipid complex are focal thickening of GBM
and mesangial proliferation. GBM is thought normally to
function as a major charge and size barrier to the filtration
of macromolecules, and its alteration causes proteinuria
[47]. In this context, the existence of a relationship
between the deformity of GBM and accelerated protein
excretion observed in our mice appears reasonable. On
the other hand, on immunoelectron microscopic analysis
we observed that the main glomerular compartment tar-
geted by our gene delivery system was glomerular epithe-
lium [see (e) in Figure 1C]. Is glomerular epithelium
injury associated with structural alteration in GBM? Hin-
glais et al. [48] suggest that glomerular epithelial cells are
partly responsible for the formation and maintenance of
the GBM by synthesizing matrix components. Glomerular
cell injuries thus compromise the integrity of the GBM,
resulting in loss of its structure and barrier function. If
glomerular epithelium and endothelium are the sites
where intravenously introduced DT-A expression plasmid
is introduced and expressed, it may be asked why electron
microscopic analysis failed to demonstrate the presence of
degenerated glomerular epithelium and endothelium. In
this study, we examined kidneys at 4 days after final intro-
duction of DT-A expression plasmid. By this time, the
damaged cells would have been removed from the
affected area and immediately replaced by proliferating
cells such a mesangial cells.
The mechanism underlying glomerular abnormalities
caused by repeated intravenous injections of DT-A
expression vector/lipid complex is as follows: i) entrap-
ping of plasmid/lipid complex by glomerular epithelial
(and probably endotherial) cells, ii) ablation of glomeru-
lar epithelial and endothelial cells due to DT-A expression
per se, iii) formation of focal deposits in GBM, leading to
elevated levels of urine proteins and occult blood, iv) pro-
liferation of neighboring mesangial cells and expansion of
mesangial matrix, which attenuates glomerular capillar-
ies, and v) normalization of mesangial cells, probably due
to apoptosis or necrosis of the proliferating mesangial
cells themselves. To examine why ablation of glomerular
epithelium (and probably endothelium) results in gener-
ation of focal deposits in GBM, introduction of a plasmid
carrying glomerular epithelium-specific promoter-
directed DT-A gene is now being performed.
Conclusions
Temporary glomerular abnormalities in mice were
induced by repeated intravenous injections of DT-A
expression vector/lipid complex. These abnormalities
resemble sub-acute glomerulonephritis. Mice with these
abnormalities will be useful as animal models in the fields
of nephrology and regenerative medicine.
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